Allosensibilisation to erythrocyte antigens (literature review)
https://doi.org/10.17650/1818-8346-2015-10-4-60-65
Abstract
In this article literature review of the causes of allosensibilisation to erythrocyte antigens are presented. It is shown that the ability to produce antierythrocyte antibodies is affected by many factors, principal of whom it is difficult to identify. For the allosensibilisation development requires genetically determined differences in erythrocyte antigens phenotypes of donor and recipient, mother and fetus, which can lead to immune response and antibodies production. The biochemical nature of erythrocyte antigens, antigen dose (the amount of transfused doses, the number of antigens determinants on donor and fetus erythrocytes, the number of pregnancies) are important. Individual patient characteristics: age, gender, diseases, the use of immunosuppressive therapy and the presence of inflammatory processes, are also relevant. Note that antibody to one erythrocyte antigens have clinical value, and to the other – have no. The actual data about frequency of clinically significant antibodies contribute to the development of post-transfusion hemolytic complications prophylaxis as well as the improvement of laboratory diagnosis of hemolytic disease of the newborn in the presence of maternal antierythrocyte antibodies.
About the Authors
N. V. Mineeva
Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency
Russian Federation
16 2nd Sovetskay St., St. Petersburg, 191024
Russian Federation
16 2nd Sovetskay St., St. Petersburg, 191024
I. A. Pashkova
Research Institute – prof. S.V. Ochapovskiy Regional Clinical Hospital No 1
Russian Federation
167 1 Мауа St., Krasnodar, 350029
Russian Federation
167 1 Мауа St., Krasnodar, 350029
I. I. Krobinets
Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency
Russian Federation
16 2nd Sovetskay St., St. Petersburg, 191024
Russian Federation
16 2nd Sovetskay St., St. Petersburg, 191024
E. A. Sysoeva
Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency
Russian Federation
16 2nd Sovetskay St., St. Petersburg, 191024
Russian Federation
16 2nd Sovetskay St., St. Petersburg, 191024
References
1. Bolton-Maggs P.H. Bullet points from SHOT: key messages and recommendations from the Annual SHOT Report 2013. Transfus Med 2013;23(4):215–6.
2. Issitt P.D., Anstree D.J. Applied blood group serology. Montgomery: Scientific Publications, 1998. Pp. 873–920.
3. Bauer M.P., Wiersum-Osselton Schipperus M., Vandenbrouke J.P., Briet E. Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion 2007;47: 2066–71.
4. Schonewille Н., van de Watering Leo M.G., Loomans Dominique S.E. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion 2006;46(2):250–6.
5. Schonewille H., Haak H., Zijl A. RBC antibody persistence. Transfusion 2000;40:1127–31.
6. Schonewille H., Doxiadis I.I., Levering W.H. et al. HLA-DRB1 associations in individuals with single and multiple clinically relevant red blood cell antibodies. Transfusion 2014;54:1971–80.
7. Verduin E.P., Schonewille H., Claas F. et al. HLA-DRB1*15 is a marker for multiple antibody responders. Vox Sang 2013;105(1):235.
8. Klein H., Anstee D., Mollison P. Blood transfusion in clinical medicine. London: Blackwell Publishing, 2005. 891 p.
9. Frohn C., Dumbgen L., Brand J.M. et al. Probability of anti-D development in D–patients receiving D+ RBCs. Transfusion 2003;43:893–8.
10. Kormoczi G., Mayr W. Responder individuality in red blood Cell alloimmunization. Transfus Med Hemother 2014;41:446–51.
11. Reid M.E., Lomas-Francis C., Olsson M.L. The Blood group antigen facts book, London: Elsevier, 2012. 561 р.
12. Poole J., Daniels G. Blood group antibodies and their significance in transfusion medicine. Transfus Med Rev 2007;21:58–71.
13. Tormey C., Stack G. Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy related antibodies. Blood 2009;114:4279–82.
14. Mintz P.D. Transfusion therapy. Clinical principles and practice. Bethesda: AABB Press, 2011. 931 р.
15. Natukunda B., Schonewille H., Watering L., Brand A. Prevalence and specificities of red blood cell alloantibodies in transfused Ugandans with different diseases. Vox Sang 2010;98:167–71.
16. Thakral B., Saluja K., Sharma R.R., Marwaha N. Red cell alloimmunization in a transfused patient population: a study from a tertiary care hospital in north India. Hematology 2008;13:313–8.
17. Milkins C., Berryman J., Cantwell C. et al. Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. BCSH guidelines. Transfus Med 2013;23:3–35.
18. Zalpuri S., Middelburg R.A., Schonewille H. et al. Intensive red blood cell transfusions and risk of alloimmunization. Transfusion 2014;54(8):1981–7.
19. Ameen R., Shemmari S., Al-Bashir A. Red blood cell alloimmunization among sickle cell Kuwaiti Arab patients who received red blood cell transfusion. Transfusion 2009;49(8):1649–54.
20. Miller S., Kim H., Weiner D. et al. Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion 2013;53(4):704–9.
21. Sanz C., Nomdedeu M., Blkaid M. et al. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion 2013;53(4):710–5.
22. Yazer M., Triulzi D. Detection of anti-D in D-recipients transfused with D+ red blood cells. Transfusion 2007;47(12):2197–201.
23. Shariatmadar S. Alloimmunization to red cell antigens in liver and multivisceral transplant patients. Transplantation 2007; 84:527–31.
24. Boctor F.N., Ali N.M., Mohandas K., Uehlinger J. Absence of D alloimmunization in AIDS patients receiving D-mismatched RBCs. Transfusion 2003;43(2):173–6.
25. Zalpuri S., Evers D., Zwaginga J.J. et al. Immunosuppressants and alloimmunization against red blood cell transfusions. Transfusion 2014;54(8):1981–7.
26. Yazer M.H., Triulzi D.J., Shaz B. et al. Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization? Transfusion 2009;49(6):1070–5.
27. Marcucci C., Madjdpour C., Spahn D.R. Allogeneic blood transfusions: benefit, risks and clinical indications in countries with a low or high human development index. Br Med Bull 2004;70:15–28.
28. Gader A.G. Transfusion medicine in a developing country – alloantibodies to red blood cells in multitransfused patients in Saudi Arabia. Transfus Apher Sci 2008;39:199–204.
29. Минеева Н.В., Гавровская С.В., Кробинец И.И. и др. Частота выявления антиэритроцитарных, антилейкоцитарных, антитромбоцитарных аллоантител у больных гематологическими заболеваниями. Онкогематология 2013;(4):13–7. [Mineeva N.V., Gavrovskaya S.V., Krobinets I.I. et al. The detection frequency of antierythrocyte, antileukocyte and antiplatelet alloantibodies in patients with hematological diseases. Onkogematologiya = Oncohematology 2013;(4):13–7. (In Russ.)].
30. Бутина Е.В., Зайцева Г.А., Удальцова В.Ф. и др. Аллосенсибилизация к антигенам эритроцитов у доноров компонентов крови и пациентов с заболеваниями системы крови. Вестник службы крови России 2012;(3):18–21. [Butina E.V., Zaytseva G.A., Udal,tsova V. F. et al. Allosensibilisation to erythrocyte antigens in the blood donors and patients with hematological diseases. Vestnik sluzhby krovi Rossii = Bulletin of Russian Blood Service 2012;(3):18–21. (In Russ.)].
31. Gottvall T., Filbey D. Alloimmunization in pregnancy during the years 1992–2005 in the central west region of Sweden. Acta Obstet Gynecol Scand 2008;87:843–8.
32. Минеева Н.В., Пашкова И.А. Специфичность аллоантител беременных женщин и особенности течения гемолитической болезни новорожденных. Гематология и трансфузиология 2002;47(6):35–6. [Mineeva N.V., Pashkova I.A. The alloantibodies specificity of pregnant women and features of newborn hemolytic disease. Gematologiya i transfuziologiya = Hematology and Transfusiology 2002;47(6):35–6. (In Russ.)].
33. Verduin E., Brand A., Middelburg R., Shonewille H. Female sex of older patients is an independent risk factor for red blood cell alloimmunization after transfusion. Transfusion 2015;55(6):1478–85.
34. Plett M., Sapp C., Hartwell B. Persistence of unexpected alloantibody in donors. Transfusion 2010;50(2):158–9.
35. Plett M., Sapp C., Nobles J. Passive antibody in patients transfused with red blood cells that contain alloantibody. Transfusion 2010;50(2):157A.
36. Минеева Н.В. Особенности исследования антител к антигенам эритроцитов у доноров. Трансфузиология 2012;13(3):14–20. [Mineeva N.V. Features of erythrocyte antibodies detection in donors. Transfuziologiya = Transfusiology 2012;13(3):14–20. (In Russ.)].
37. Пашкова И.А., Рыжанова Л.Г., Федоренко Т.В. и др. Анализ специфичности аллоиммунных антител, выявленных у реципиентов. Гематология и трансфузиология 2009;(5):31–4. [Pashkova I.A., Ryzhanova L.G., Fedorenko T.V. et al. Analysis of alloimmune antibodies specificity identified in recipients. Gematologiya i transfuziologiya = Hematology and Transfusiology 2009;(5):31–4. (In Russ.)].
Review
For citations:
Mineeva N.V., Pashkova I.A., Krobinets I.I., Sysoeva E.A. Allosensibilisation to erythrocyte antigens (literature review). Oncohematology. 2015;10(4):60-65. (In Russ.) https://doi.org/10.17650/1818-8346-2015-10-4-60-65
Views:
10669
Email this article 